METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.
Keep Reading
A global survey shows robot anxiety drops when people encounter robots in real life
Updated
April 1, 2026 8:55 AM

Ameca the humanoid robot, featuring a grey rubber face. PHOTO: ADOBE STOCK
People often assume robots make people uneasy everywhere. But a new global study suggests something more nuanced. Robot anxiety tends to be highest in places where people rarely see robots in real life. Where robots are more visible, attitudes are often far more positive. That insight comes from a global study by Hexagon AB, which surveyed 18,000 participants across nine major markets. The research explored how adults and children think about robots and how those views change depending on everyday exposure.
In the United Kingdom, anxiety about robots is the highest among the countries studied. Around 52% of adults say they feel worried that something might go wrong when they think about interacting with or working alongside robots. South Korea sits at the other end of the spectrum, with only 29% reporting similar concerns. One factor appears to explain much of the gap: familiarity.
British adults are among the least likely to have encountered robots in real life. Only about 30% say they have seen or used one. In contrast, countries where robots are more visible tend to report greater comfort. China offers the clearest example. Around 75% of adults there say they have seen or interacted with robots. At the same time, 81% say they feel excited about the technology’s future potential.
The study suggests that attitudes toward robots are not fixed. Instead, they shift depending on where people encounter them and what tasks they perform. When robots are seen solving clear, practical problems, confidence tends to rise.
Across the surveyed countries, adults report the highest comfort levels with robots working in factories and warehouses. Around 63% say they are comfortable with robots in those environments. These are settings where tasks are clearly defined and safety standards are well understood. Acceptance drops in more personal spaces. Only 46% say they feel comfortable with robots in the home, while comfort falls further to 39% when robots are imagined in classrooms.
In other words, context matters. People appear more willing to accept robots when they take on physically demanding or dangerous work. Half of the respondents say improved safety is one of the main advantages of robotics in those environments. A similar share point to productivity gains as another benefit. Another finding challenges a common assumption about public fears. Job loss is often described as the biggest concern surrounding robotics. But the study suggests security risk worries people more.
Around 51% of adults say their biggest concern about robots at work is the possibility that the machines could be hacked or misused. That fear outweighs worries about physical malfunction or injury, which stand at 41%. Concerns about being replaced at work appear at the same level.
For many respondents, the issue is not simply whether robots can perform tasks. It is whether the systems controlling them are secure. According to researchers involved in the study, these concerns reflect how people evaluate emerging technologies. Instead of having a single opinion about robotics, people tend to judge each situation individually.
A robot helping assemble products in a factory may feel acceptable. The same technology operating in more sensitive environments can raise different questions. Dr. Jim Everett, an associate professor in moral psychology, says trust in artificial intelligence and robotics is often misunderstood. People are not simply asking whether they trust the technology, he notes. They are thinking about specific tools performing specific roles.
A robot assisting in a classroom or helping in healthcare carries different expectations than an AI system used in defense or surveillance. Even though these technologies are often grouped together in public debates, people evaluate them differently depending on their purpose.
Finally, the study also highlights another important factor shaping public attitudes: experience. When people actually encounter robots, fear often declines. Michael Szollosy, a robotics researcher involved in the project, says reactions tend to change quickly when individuals meet a robot for the first time.
The idea of an autonomous machine can feel intimidating in theory. But when people see a small service robot or an industrial machine performing a straightforward task, the reaction is often much calmer. Exposure can shift perceptions from abstract fears to practical understanding.
That shift matters because robotics is moving steadily into everyday environments. From manufacturing and logistics to healthcare and public services, machines capable of autonomous or semi-autonomous work are becoming more common.
As that happens, the study suggests public confidence may depend less on technical breakthroughs and more on visibility and transparency. Burkhard Boeckem, chief technology officer at Hexagon AB, argues that trust grows when people understand what robots are designed to do and where their limits lie.
Anxiety tends to increase when systems feel invisible or poorly understood. Clear boundaries and clear explanations can have the opposite effect. When people see robots working safely alongside humans, performing well-defined tasks and operating within clear rules, the technology becomes easier to accept.
In that sense, the future of robotics may depend as much on public familiarity as on engineering. The machines themselves are advancing quickly. But the relationship between humans and robots is still being negotiated. For now, the study offers a simple insight: the more people encounter robots in everyday life, the less mysterious they become. And once the mystery fades, the conversation often changes from fear to curiosity.